Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Change in fair value recognized in net earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Projected year of payments Projected Year of Payments [Member] Represents projected year of payments. Net earnings attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Changes in operating assets and liabilities, net of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Acquired IPR&D and milestones Research and Development Asset Acquired Other than Through Business Combination, Writeoff Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Revolving Credit Facility Revolving Credit Facility [Member] Effect of exchange rate changes on cash and equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Deferred income taxes Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Transfers of assets out of Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Prepaid expenses and other Prepaid Expenses and Other Current Assets [Member] Restatement Determination Date: Restatement Determination Date [Axis] Foreign currency translation adjustments, tax expense (benefit) Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Number of claims pending Loss Contingency, Pending Claims, Number U.S. statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Commitments and contingencies Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Geographical [Axis] Geographical [Axis] Pre-tax gains (losses) to be transferred into net foreign exchange gain/loss for cross-currency swap contract cash flow hedges during the next 12 months Cross-Currency Swap Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 12 Months Cross-Currency Swap Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 12 Months Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Income Taxes Income Tax Disclosure [Text Block] Sec 2.125 Senior Notes Due 2029 Sec 2.125 Senior Notes Due 2029 [Member] Sec 2.125 Senior Notes Due 2029 Concentration of Risk Concentration Risk [Line Items] Customer [Axis] Customer [Axis] Current liabilities Liabilities, Current [Abstract] Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss Duodopa Duodopa [Member] Represents information pertaining to Duodopa, a product of the entity. Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Inventories Inventory, Net [Abstract] Payments of contingent consideration liabilities Payment for Contingent Consideration Liability, Financing Activities Gain (loss) on derivatives Derivative Instruments, Gain (Loss) [Line Items] Diluted earnings per share (in dollars per share) Earnings Per Share, Diluted Fair value - Derivatives in liability position Foreign currency contracts Derivative Liability, Subject to Master Netting Arrangement, before Offset PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Common stock held in treasury, at cost, 57,127,750 shares as of June 30, 2023 and 44,589,000 as of December 31, 2022 Treasury Stock, Value Accounts receivable, net AbbVie's receivable from Janssen Accounts Receivable, after Allowance for Credit Loss, Current Changes in the carrying amount of goodwill Goodwill [Roll Forward] Summary of quarterly cash dividends Schedule of Dividends Payable [Table Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Treasury Stock, Common, Shares Treasury Stock, Common, Shares Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans Schedule of Net Benefit Costs [Table Text Block] Janssen Biotech Inc. Janssen Biotech Inc [Member] Represents the information pertains to the entity Janssen Biotech Inc. Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol Restructuring Plan [Domain] Restructuring Plan [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Money market funds and time deposits Investments, Fair Value Disclosure Weighted-average grant-date fair value of the stock options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net earnings attributable to AbbVie Inc. Net earnings attributable to AbbVie Inc. Total reclassifications, net of tax Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract Type [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name 2.8% senior notes due 2023 Senior Notes Due 2023 At 2.800 Percent [Member] Senior Notes Due 2023 At 2.800 Percent Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Total intangible assets gross carrying amount Intangible Assets, Gross (Excluding Goodwill) Aggregate principal amount outstanding Debt and Lease Obligation Liabilities and Equity Liabilities and Equity [Abstract] Finite-Lived Intangible Assets Finite-Lived Intangible Assets [Line Items] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Stockholders' equity Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Significant amounts reclassified out of each component of AOCI Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Schedule of basic and diluted earnings per share, impact of two-class method Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of products sold Losses (gains) on foreign currency forward exchange contracts Cost of Goods and Services Sold Service cost Defined Benefit Plan, Service Cost Executive Category: Executive Category [Axis] Summary of indefinite-lived intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Other restructuring Other Restructuring Plans [Member] Represents other restructuring plans. Dividends [Domain] Dividends [Domain] Foreign currency contracts Foreign Exchange Contract [Member] Quoted prices in active markets for identical assets (Level 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Imbruvica Imbruvica [Member] Represents information pertaining to Imbruvica, a product of the entity. Name Forgone Recovery, Individual Name Book value Reported Value Measurement [Member] Ozurdex Ozurdex [Member] Ozurdex Goodwill Balance at the beginning of the period Balance at the end of the period Goodwill Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Investment Type [Axis] Investment Type [Axis] Amount excluded from the assessment of effectiveness for fair value hedges Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net Measurement Basis [Axis] Measurement Basis [Axis] Stock options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold Maximum Length of Time Hedged in Cash Flow Hedge Investments [Domain] Investments [Domain] Juvise Pharmaceuticals Juvise Pharmaceuticals [Member] Juvise Pharmaceuticals Number of individual plaintiff lawsuits Loss Contingency Individual Plaintiff Lawsuits Number Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period. Charges associated with integration or restructuring plans Restructuring and Related Cost, Incurred Cost Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Cash dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Accounts receivable, net Accounts Receivable [Member] Notional amount of derivative instruments Derivative, Notional Amount Selling, general and administrative Selling, General and Administrative Expenses [Member] Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Measurement Frequency [Axis] Measurement Frequency [Axis] Number of generic companies with whom certain litigation related agreements were entered into Loss Contingency Number of Generic Companies as Counterparty of Litigation Related Agreements Violated Certain Laws Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws. Fair Value Measurement Inputs and Valuation Techniques [Abstract] Fair Value Measurement Inputs and Valuation Techniques [Abstract] Share of collaboration development costs responsible by Janssen (as a percent) Collaborative Arrangements Percentage Of Share Of Development Costs Responsible By Third Party Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement. Retirement Plan Type [Domain] Retirement Plan Type [Domain] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Term loan credit agreement term Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Depreciation Depreciation expense Depreciation Amortization of actuarial losses and other Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Portion at fair value measurement Portion at Fair Value Measurement [Member] Income Statement Location [Axis] Income Statement Location [Axis] Mavyret MAVYRET [Member] Represents information pertaining to MAVYRET, a product of the entity. Floating rate notes due 2025 Floating Rate Term Loan Tranche Due May 2025 [Member] Floating Rate Term Loan Tranche Due May 2025 Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Change in noncontrolling interest Noncontrolling Interest, Period Increase (Decrease) Research and development Research and Development Expense (Excluding Acquired in Process Cost) After-tax compensation expense Share-Based Payment Arrangement, Expense, after Tax Allergan integration plan Allergan Integration Plan [Member] Represents information pertaining to the Allergan integration plan. Foreign currency forward exchange contracts Foreign Exchange Forward [Member] Net revenues Total net revenues Revenues Schedule of book values, approximate fair values and bases used to measure certain financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Short-Term Borrowings [Line Items] Short-Term Debt [Line Items] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories Increase (Decrease) in Inventories Research and development Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Accrued balance beginning of the period Accrued balance end of the period Restructuring Reserve Cross-currency swap contracts Derivative Assets, Cross-Currency Swap Contracts Derivative Assets, Cross-Currency Swap Contracts Award Type [Axis] Award Type [Axis] Shares granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report International - AbbVie's share of profits (included in net revenues) Collaboration revenues Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Interest expense Interest Expense Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Hedging Designation [Axis] Hedging Designation [Axis] Sec 2.125 Senior Notes due 2028 Sec 2.125 Senior Notes due 2028 [Member] Sec 2.125 Senior Notes due 2028 [Member] Property and equipment, gross Property, Plant and Equipment, Gross Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Significant unobservable input for contingent consideration Business Combination, Contingent Consideration, Liability, Measurement Input Schedule of interest expense, net Interest Income and Interest Expense Disclosure [Table Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Ubrelvy Ubrelvy [Member] Represents information pertaining to Ubrelvy, a product of the entity. Prescription drug abuse litigation in state courts Prescription Drug Abuse Litigation In State Courts [Member] Prescription Drug Abuse Litigation In State Courts Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Derivative instruments, notional amount and fair value Derivatives, Fair Value [Line Items] Neuroscience Neuroscience [Member] Represents information pertaining to Neuroscience, a key product portfolio of the entity. Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract] Other Comprehensive Income (Loss), Tax, Parenthetical Disclosure [Abstract] Discount rate Measurement Input, Discount Rate [Member] Duration of forward exchange contracts Derivative, Term of Contract Other Aesthetics Other Aesthetics [Member] Represents information pertaining to Other Aesthetics products. Niaspan Niaspan [Member] Represents information pertaining to Niaspan, a product of the entity. Income tax assets and liabilities, net Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable Amortization of intangible assets Amortization expense Amortization of Intangible Assets Entity Shell Company Entity Shell Company Investments Long-Term Investments Net carrying amount Finite-Lived Intangible Assets, Net Restatement Determination Date Restatement Determination Date Probability of payment for royalties excluding approved indications Probability of Payment for Royalties Excluding Approved Indications [Member] Represents estimated probability of payment for royalties excluding approved indications. Other operating income (expense) Other Operating Income (Expense) [Member] Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and equivalents, beginning of period Cash and equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Non-cash litigation reserve adjustments, net of cash payments Non-cash litigation reserve adjustments, net of cash payments Non-cash litigation reserve adjustments, net of cash payments Dividend Declared [Member] Dividend Declared [Member] Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Term loan facilities Loans Payable [Member] Common stock, issued (in shares) Common Stock, Shares, Issued Sales and maturities of investment securities Proceeds from Sale, Maturity and Collection of Investments Current portion of long-term debt and finance lease obligations Long-Term Debt and Lease Obligation, Current Alphagan/Combigan Alphagan/Combigan [Member] Represents information pertaining to Alphagan/Combigan, a product of the entity. Security Exchange Name Security Exchange Name Other Neuroscience Other Neuroscience [Member] Represents information pertaining to Other Neuroscience products. Long-term debt obligations, gross Long-Term Debt Total assets Assets, Fair Value Disclosure Botox Therapeutic Botox Therapeutic [Member] Represents information pertaining to Botox Therapeutic, a product of the entity. Diluted EPS Earnings Per Share, Diluted, Two Class Method [Abstract] Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Collaborations Collaborative Arrangement Disclosure [Text Block] Stock Options Employee Stock Option [Member] Dividends Payable Dividends Payable [Line Items] Interest rate swap contracts Interest Rate Derivative Liabilities, at Fair Value Period for recognition of unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total operating costs and expenses Costs and Expenses Other, net Proceeds from (Payments for) Other Financing Activities Incurred total cumulative integration charges Restructuring and Related Cost, Cost Incurred to Date Maximum Maximum [Member] Comprehensive income attributable to AbbVie Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Summary of charges associated with integration plan Restructuring and Related Costs [Table Text Block] AGN-151607 AGN-151607 [Member] AGN-151607 Property and Equipment Property, Plant and Equipment, Net [Abstract] Document Type Document Type Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Geographic risk Geographic Concentration Risk [Member] Tabular List, Table Tabular List [Table Text Block] Hematologic Oncology Hematologic Oncology [Member] Represents information pertaining to Hematologic Oncology, a key product portfolio of the entity. Entity Address, Address Line One Entity Address, Address Line One Purchases of treasury stock Payment for shares repurchased Treasury Stock, Value, Acquired, Cost Method Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss [Abstract] Amortization of actuarial loss Defined Benefit Plan, Amortization Of Actuarial Gain (Loss), Prior Service Cost (Credit) The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost. Equity Share-Based Payment Arrangement [Text Block] Other, net Other Noncash Income (Expense) Net investment hedging activities Accumulated Net Gain (Loss) From Net Investment Hedges [Member] Accumulated Net Gain (Loss) From Net Investment Hedges Prescription drug abuse litigation Prescription Drug Abuse Litigation [Member] Represents information pertaining to prescription drug abuse litigation. Interest Expense, Net Interest Revenue (Expense), Net [Abstract] Sec 1.500 Senior Notes Due 2023 Sec 1.500 Senior Notes Due 2023 [Member] Sec 1.500 Senior Notes Due 2023 Derivative [Table] Derivative [Table] Other Key Products Other Key Products [Member] Represents information pertaining to other key products of the entity. NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Summary of definite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Title of 12(b) Security Title of 12(b) Security Restructuring charges Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash and equivalents Cash and Cash Equivalents, Fair Value Disclosure Summary of cash activity in the restructuring reserve Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Licensing, Acquisitions, and Other Arrangements Licensing, Acquisitions, and Other Arrangements Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Fair market value of awards vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Genentech, Inc. Genentech, Inc. [Member] Genentech, Inc. [Member] Stock-based compensation plans and other Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Number of purported class actions Loss Contingency Purported Class Actions Number Represents the number of purported class actions filed, pertaining to a loss contingency during the period. Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Dividends Payable [Table] Dividends Payable [Table] Net foreign exchange loss Foreign Currency Gain (Loss) [Member] Entity Tax Identification Number Entity Tax Identification Number Inventories Inventories Inventory, Net Purchases of investment securities Payments to Acquire Marketable Securities Statistical Measurement [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Adjustments to reconcile net earnings to net cash from operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount Purchases of treasury stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Transfers of liabilities into Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 Pension and post-employment benefits, tax expense (benefit) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Creon Creon [Member] Represents information pertaining to Creon, a product of the entity. Share-based Compensation Arrangement by Share-based Payment Award Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Floating rate notes due 2025, refinanced Floating Rate Term Loan Tranche Due May 2025, Refinanced [Member] Floating Rate Term Loan Tranche Due May 2025, Refinanced Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Basic EPS Earnings Per Share, Basic, Two Class Method [Abstract] Transfers of assets into Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Principal amount of unsecured senior notes Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets Assets, Current [Abstract] Restructuring costs location [Domain] Restructuring costs location [Domain] Restructuring costs location [Domain] Equity securities Equity Securities, FV-NI Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Immunology Immunology [Member] Represents information pertaining to Immunology, a key product portfolio of the entity. Skyrizi SKYRIZI [Member] Represents information pertaining to SKYRIZI, a product of the entity. AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) Selling, General And Administrative Expense From Collaborative Arrangements Amount of selling, general and administrative expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. Transfers of liabilities out of Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 Interest cost Defined Benefit Plan, Interest Cost PEO PEO [Member] Litigation charge related to potential settlement Loss Contingency, Estimate of Possible Loss Defined benefit and other post-employment plans Defined Benefit Plan Disclosure [Line Items] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) [Line Items] Foreign currency translation adjustments Goodwill, Other Increase (Decrease) Fair value - Derivatives in asset position Foreign currency contracts Derivative Asset, Subject to Master Netting Arrangement, before Offset Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Customer [Domain] Customer [Domain] Earnings available to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Schedule of inventories Schedule of Inventory, Current [Table Text Block] Interest rate swap contracts Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months Treasury Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Treasury Rate Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Collaborative arrangement Collaborative Arrangement [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate Effective Income Tax Rate Reconciliation, Percent Lumigan/Ganfort Lumigan/Ganfort [Member] Represents information pertaining to Lumigan/Ganfort, a product of the entity. Measurement Input Type [Domain] Measurement Input Type [Domain] Credit Facility [Axis] Credit Facility [Axis] Cash flow hedging activities, tax expense (benefit) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Milestone payments Collaborative Arrangement Milestone Method Payments Receivable The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement. Fair Value Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Aesthetics Aesthetics [Member] Represents information pertaining to Aesthetics, a key product portfolio of the entity. Tax benefit Share-Based Payment Arrangement, Expense, Tax Benefit CHICAGO STOCK EXCHANGE, INC NYSE CHICAGO, INC. [Member] Per share data Earnings Per Share [Abstract] AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. AndroGel Antitrust Litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. [Member] Represents information pertaining to AndroGel antitrust litigation filed under King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. Potential change in unrecognized tax benefits Decrease in Unrecognized Tax Benefits is Reasonably Possible Treasury rate lock agreements Treasury Lock [Member] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements [Abstract] Legal Proceedings and Contingencies Legal Matters and Contingencies [Text Block] Net investment hedging activities, net of tax expense (benefit) of $2 for the three months and $(58) for the six months ended June 30, 2023 and $146 for the three months and $183 for the six months ended June 30, 2022 Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), After Reclassification and Tax Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior notes Senior Notes [Member] Total current assets Assets, Current Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Net periodic benefit cost (credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) Cost of Goods And Services Sold From Collaborative Arrangements Amount of costs of goods and services sold arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. Juvederm Collection Juvederm Collection [Member] Represents information pertaining to Juvederm Collection, a product of the entity. Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Contingent consideration Business Combination, Contingent Consideration, Liability All Individuals All Individuals [Member] Litigation Case Type [Domain] Litigation Case [Domain] Other expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Global - AbbVie's share of other costs (included in respective line items) Other Expenses From Collaborative Arrangements Amount of other expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] PEO Name PEO Name Concentrations risk (as a percent) Concentration Risk, Percentage Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Summary of changes in balances of each component of accumulated other comprehensive loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Summary of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Other post-employment plans Other Postretirement Benefits Plan [Member] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock [Axis] Class of Stock [Axis] Entities [Table] Entities [Table] Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Acquisitions and investments Cash outflows related to acquisitions and investments Payments to Acquire Other Investments Amortization of prior service cost (credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) HUMIRA Product Concentration Risk [Member] All other Other Products [Member] Represents information pertaining to other products of the entity not specified anywhere. Financial Instruments and Fair Value Measures Derivatives and Fair Value [Text Block] Long-term debt and finance lease obligations, excluding fair value hedges Long Term Debt and Capital Lease Obligations Fair Value Disclosure Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date. Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted Gain on divestitures Gain on divestitures Gain (Loss) on Disposition of Other Assets Other operating income Other Operating Income (Expense), Net Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Accounts payable and accrued liabilities AbbVie's payable to Janssen Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Information Entity Information [Line Items] Postemployment Benefits [Abstract] Postemployment Benefits [Abstract] Supplemental Financial Information Supplemental Financial Information Total stockholders' equity Equity, Attributable to Parent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Summary of significant level 3 unobservable inputs Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Restasis Restasis [Member] Represents information pertaining to Restasis, a product of the entity. Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Long-term debt and finance lease obligations Long-Term Debt and Lease Obligation Earnings before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Tax court petition Tax court petition [Member] Tax court petition Net investment hedging activities AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member] Carrying amount of investments in equity securities that do not have readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Not designated as hedging instrument Not designated as hedges Not Designated as Hedging Instrument [Member] Integration and Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Hedging Designation [Domain] Hedging Designation [Domain] Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Significant other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Net investment hedges Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Probability of payment for unachieved milestones Probability of Payment for Unachieved Milestones [Member] Represents the probability of payment for unachieved milestones Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities [Member] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other assets Other Noncurrent Assets [Member] Floating rate notes due 2023, refinanced Floating Rate Term Loan Tranche Due May 2023, Refinanced [Member] Floating Rate Term Loan Tranche Due May 2023, Refinanced Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Other Collaboration Arrangements Other Collaboration Arrangements [Member] Represents information relating to the series of other collaborative arrangements. Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] 3.45% senior notes due 2022 Senior Notes Due 2022 At 3.450 Percent [Member] Senior Notes Due 2022 At 3.450 Percent Sec 1.375 Senior Notes Due 2024 Sec 1.375 Senior Notes Due 2024 [Member] Sec 1.375 Senior Notes Due 2024 [Member] Title Trading Arrangement, Individual Title Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Linzess/Constella Linzess/Constella [Member] Represents information pertaining to Linzess/Constella, a product of the entity. Weighted average Weighted Average [Member] Current portion of long-term debt and finance lease obligations, excluding fair value hedges Long Term Debt and Capital Lease Obligations Current Fair Value Disclosure Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future. Common stock Common Stock [Member] Pension and post-employment benefits, net of tax expense (benefit) of $(4) for the three months and $10 for the six months ended June 30, 2023 and $11 for the three months and $21 for the six months ended June 30, 2022 Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Earnings Per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Schedule of changes in fair value of Level 3 inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Schedule of profit and cost sharing relationship Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Qulipta Qulipta [Member] Qulipta AbbVie's share of development costs (included in R&D) Research And Development Expense From Collaborative Arrangements Amount of research and development expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. Minimum Minimum [Member] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Share Repurchase Program [Domain] Share Repurchase Program [Domain] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Other comprehensive loss Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Basic Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Equity, Class of Treasury Stock Equity, Class of Treasury Stock [Line Items] Dividends declared Dividends, Common Stock, Cash Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Short-term borrowings Short-Term Debt, Fair Value Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Total liabilities Liabilities, Fair Value Disclosure Summary of amounts and location of derivatives on the condensed consolidated balance sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Net foreign exchange loss Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Gain (Loss), Foreign Currency Transaction, before Tax Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Restructuring costs location [Axis] Restructuring costs location [Axis] Restructuring costs location Net earnings Net earnings Net earnings Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Retirement Plan Type [Axis] Retirement Plan Type [Axis] Foreign currency translation adjustments, net of tax expense (benefit) of $(6) for the three months and $6 for the six months ended June 30, 2023 and $(12) for the three months and $(19) for the six months ended June 30, 2022 Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Other, net Payments for (Proceeds from) Other Investing Activities Transfers of assets or liabilities between the fair value measurement levels Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract] Developed product rights Developed Technology Rights [Member] Retained earnings Retained Earnings [Member] RSUs and Performance Shares Restricted Stock Units And Performance Shares [Member] Restricted Stock Units And Performance Shares [Member] Summary of share-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and equity Liabilities and Equity Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Cash flow hedging activities, net of tax expense (benefit) of $(4) for the three months and $(8) for the six months ended June 30, 2023 and $5 for the three months and $3 for the six months ended June 30, 2022 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Basic earnings per share (in dollars per share) Earnings Per Share, Basic Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Long-Term Debt Schedule of Long-Term Debt Instruments [Table] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Research and development milestone expenses Research and Development Milestone Expenses Research and Development Milestone Expenses Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Earnings available to common shareholders Net Income (Loss) Available to Common Stockholders, Diluted Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Amount excluded from the assessment of effectiveness for cash flow hedges Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net Rinvoq RINVOQ [Member] Represents information pertaining to RINVOQ, a product of the entity. Bystolic antitrust litigation Bystolic Antitrust Litigation [Member] Represents information pertaining to Bystolic antitrust litigation. Repayments of long-term debt Proceeds from (Repayments of) Long-Term Debt and Capital Securities Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Interest expense, net Interest Expense [Member] Remaining share repurchase authorization amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Common stock, authorized (in shares) Common Stock, Shares Authorized Debt securities Debt Securities, Available-for-Sale Cross-currency swap contracts Cross-Currency Swap Contracts [Member] Cross-Currency Swap Contracts Short-term borrowings Short-Term Debt Fair value, asset and liability measures Bases used to measure the approximate fair values of the financial instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss) Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Other Eye Care Other Eye Care [Member] Represents information pertaining to Other Eye Care products. Botox Cosmetic Botox Cosmetic [Member] Represents information pertaining to Botox Cosmetic, a product of the entity. Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Derivative Instrument [Axis] Derivative Instrument [Axis] Share of collaboration development costs responsible by the entity (as a percent) Collaborative Arrangements Percentage Of Share Of Development Costs Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement. Licensing, Acquisitions, and Other Arrangements Acquisitions Collaborations and Other Arrangements Disclosure [Text Block] The entire disclosure for acquisitions, collaborations and other arrangements of the entity. Key Product Portfolio [Axis] Key Product Portfolio [Axis] Information concerning the company's portfolios of key products. All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] All Adjustments to Compensation All Adjustments to Compensation [Member] Tax benefit Reclassification from AOCI, Current Period, Tax Restructuring reserve rollforward Restructuring Reserve [Roll Forward] Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,821,926,709 shares issued as of June 30, 2023 and 1,813,770,294 as of December 31, 2022 Common Stock, Value, Outstanding Award Timing Disclosures [Line Items] Key Product Portfolio [Domain] Key Product Portfolio [Domain] [Domain] for Information concerning the company's portfolios of key products. Compensation Amount Outstanding Recovery Compensation Amount Comprehensive income attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Principal US customers Principal US Customers [Member] Principal US Customers Humira H U M I R A [Member] Represents information pertaining to HUMIRA, a product of the entity. Sec 1.250 Senior Notes Due 2024 Sec 1.250 Senior Notes Due 2024 [Member] Sec 1.250 Senior Notes Due 2024 Deferred income taxes Deferred Income Tax Expense (Benefit) Restructuring Plan [Axis] Restructuring Plan [Axis] Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Increase to existing stock repurchase authorization Stock Repurchase Program Increase In Authorized Amount Stock Repurchase Program Increase In Authorized Amount Number of healthcare benefit providers acting as plaintiff in lawsuit Loss Contingency, Number of Plaintiffs Senior Notes Due 2023 At 2.850 Percent Senior Notes Due 2023 At 2.850 Percent [Member] Senior Notes Due 2023 At 2.850 Percent Insider Trading Arrangements [Line Items] Stock-based compensation plans and other (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Payments and other adjustments Restructuring Reserve Period Cash Settled and Other Adjustments The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period. Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Line of Credit Facility, Expiration Period Line of Credit Facility, Expiration Period Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of products sold Cost of Sales [Member] Change in fair value of contingent consideration liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Exchange [Domain] Exchange [Domain] Noncontrolling interest Equity, Attributable to Noncontrolling Interest Repayments of long-term debt and finance lease obligations Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Treasury Stock, Common Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Reclassification out of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Member] Liabilities Liabilities, Fair Value Disclosure [Abstract] Probability of payment for royalties by indication Probability of Payment for Royalties by Indication [Member] Represents probability of payment for royalties by indication. Derivative instrument net gains (losses) recognized in the consolidate statements of earnings Derivative, Gain (Loss) on Derivative, Net Pre-tax compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross carrying amount Finite-Lived Intangible Assets, Gross Income tax expense Tax expense (benefit) Income Tax Expense (Benefit) International Non-US [Member] Finished goods Inventory, Finished Goods, Net of Reserves Designated as hedging instrument Designated as Hedging Instrument [Member] Number of operating segments Number of Operating Segments Cash flow hedging activities Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Total revenues Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Net gains reclassified from accumulated other comprehensive loss Total reclassifications, net of tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Schedule of worldwide net revenues Disaggregation of Revenue [Table Text Block] Net revenues Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Sec 2.625 Senior Notes Due 2028 Sec 2.625 Senior Notes Due 2028 [Member] Sec 2.625 Senior Notes Due 2028 Money market funds and time deposits Money Market Funds [Member] Fair value hedges Fair Value Hedging [Member] Cash and equivalents Cash and Cash Equivalents, at Carrying Value License agreements Licensing Agreements [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Number of principal customers Number of Principal US Customers Represents the number of principal U.S. customers of the entity. Assets Assets, Fair Value Disclosure [Abstract] Credit Facility [Domain] Credit Facility [Domain] Purchases of treasury stock (in shares) Shares repurchased (in shares) Treasury Stock, Shares, Acquired Vraylar Vraylar [Member] Represents information pertaining to Vraylar, a product of the entity. Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Weighted-average diluted shares outstanding (in shares) Weighted-average diluted shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Collaborative Arrangements Syndesi Syndesi [Member] Syndesi Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Sec 0.750 Senior Notes Due 2027 Sec 0.750 Senior Notes Due 2027 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Interest expense, net Interest expense, net Gains on derivative amount excluded from effectiveness testing Interest Income (Expense), Nonoperating, Net Acquisitions of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Other long-term liabilities Other Liabilities [Member] Legal Proceedings and Contingencies Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] United States UNITED STATES Pension and post-employment benefits Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Fair Value, Recurring Fair Value, Recurring [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Dividends paid Payments of Dividends Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] December 2018 Stock Repurchase Authorization December 2018 Stock Repurchase Authorization [Member] December 2018 Stock Repurchase Authorization Short-term investments Short-Term Investments Defined benefit plans Pension Plan [Member] Cash flow hedges Cash Flow Hedging [Member] Segment Information Segment Reporting Disclosure [Text Block] Net change in cash and equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Work-in-process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt and Credit Facilities [Line Items] Debt Instrument [Line Items] Weighted-average basic shares outstanding (in shares) Weighted-average basic shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Potential payments under agreement certain milestones Potential Payments under Agreement Certain Milestones The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period. Operating earnings Operating Income (Loss) Short-Term Borrowings [Table] Schedule of Short-Term Debt [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Accumulated other comprehensive income (loss) AOCI Including Portion Attributable to Noncontrolling Interest [Member] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Prepaid expenses and other Prepaid Expense and Other Assets Proceeds from sale of assets Proceeds from Sale of Other Assets Venclexta VENCLEXTA [Member] Represents information pertaining to VENCLEXTA, a product of the entity. Sec 1.250 Senior Notes due 2031 Sec 1.250 Senior Notes due 2031 [Member] Sec 1.250 Senior Notes due 2031 [Member] Collaborative and license agreements Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Approximate fair value Estimate of Fair Value Measurement [Member] Eye Care Eye Care [Member] Represents information pertaining to Eye Care, a key product portfolio of the entity. Dividends [Axis] Dividends [Axis] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Long-Term Line of Credit Long-Term Line of Credit Restructuring charges Restructuring Reserve Cash Settled Restructuring Gains (Losses) The change in the restructuring reserve related to the amount of restructuring gains (losses) during the period that are expected to be cash settled. Net investment hedging activities, tax expense (benefit) Other Comprehensive Income (Loss), Net Investment Hedge, Tax Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge. Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Noncontrolling interest Noncontrolling Interest [Member]